RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
Thromb Haemost 2002; 87(03): 536-537
DOI: 10.1055/s-0037-1613036
DOI: 10.1055/s-0037-1613036
Letters to the Editor
Enoxaparin Sodium Improves Pregnancy Outcome in Aspirin-resistant Antiphospholipid/Antiprotein Antibody Syndromes
Weitere Informationen
Publikationsverlauf
Received
02. August 2001
Accepted after revision
12. Dezember 2001
Publikationsdatum:
14. Dezember 2017 (online)
-
References
- 1 Kutteh WH. Antiphopholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
- 2 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies. . Br Med J 1997; 314: 253-7.
- 3 Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled study. Am J Obstet Gynecol 2000; 183: 1008-12.
- 4 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
- 5 Gris JC, Quéré I, Sanmarco M, Boutière B, Mercier E, Amiral J, Hubert AM, Ripart-Neveu S, Hoffet M, Tailland L, Rousseau O, Monpeyroux F, Dauzat M, Sampol J, Daurès JP, Berlan J, Marès P. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. NOHA4. Thromb Haemost 2000; 84: 228-36.
- 6 Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113-7.
- 7 Meli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K. The Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191-202.